On November 6, 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported interim safety and efficacy results from the VICTORIA-01 Phase 1 clinical study of SOT201, a PD-1 targeting IL-15 immunocytokine, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting taking place November 6-8, 2026, in Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Interim Phase 1 VICTORIA-01 data showed a 59% disease control rate with SOT201 among 22 patients with advanced solid tumors who had received a median of three prior treatment lines. Two patients achieved confirmed partial responses following prior checkpoint inhibitor therapy: an esophageal cancer response lasting 388 days and a cervical cancer response ongoing at 87 days. Most treatment-related adverse events were Grade 1 or 2. The findings supported a recommended dose of 80 µg/kg with a 20 µg/kg priming dose for further evaluation.
"Both IL-15 agonism and PD-1 inhibition have robust clinical validation in immuno-oncology, and SOT201 builds on this foundation by combining PD-1 and IL-15 mechanisms to reinvigorate antitumor T cell activities and to elicit deep antitumor immune responses," said Vivi Boura, M.D., Ph.D., chief medical officer of SOTIO. "These initial clinical data support continued evaluation of SOT201 in expanded patient cohorts, and we look forward to further characterizing its potential in challenging solid tumor types."
Presentation details are as follows:
Poster Title: "Interim safety and efficacy results of VICTORIA-01: A phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors"
Poster Number: 1180
Presenter: Dr. Aung Naing, Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, Texas
Date: Saturday, Nov. 7, 2026
In additional poster presentations at SITC (Free SITC Whitepaper), SOTIO will share research on the localization of tertiary lymphoid structures (TLS) in immune checkpoint-resistant cancer types, as well as the role of PD-L1+ macrophages in shaping TLS organization in ovarian cancer metastases.
(Press release, SOTIO, NOV 6, 2026, View Source [SID1234674423])